Recent Progress in Ferroptosis Inducers for Cancer Therapy
- PMID: 31595562
- DOI: 10.1002/adma.201904197
Recent Progress in Ferroptosis Inducers for Cancer Therapy
Abstract
Ferroptosis is a newly discovered form of regulated cell death that is the nexus between metabolism, redox biology, and human health. Emerging evidence shows the potential of triggering ferroptosis for cancer therapy, particularly for eradicating aggressive malignancies that are resistant to traditional therapies. Recently, there has been a great deal of effort to design and develop anticancer drugs based on ferroptosis induction. Recent advances of ferroptosis-inducing agents at the intersection of chemistry, materials science, and cancer biology are presented. The basis of ferroptosis is summarized first to highlight the feasibility and characteristics of triggering ferroptosis for cancer therapy. A literature review of ferroptosis inducers (including small molecules and nanomaterials) is then presented to delineate their design, action mechanisms, and anticancer applications. Finally, some considerations for research on ferroptosis inducers are spotlighted, followed by a discussion on the challenges and future development directions of this burgeoning field.
Keywords: cancer therapy; ferroptosis inducers; iron metabolism; nanomedicine; tumor microenvironment.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Ferroptosis in cancer therapeutics: a materials chemistry perspective.J Mater Chem B. 2021 Nov 10;9(43):8906-8936. doi: 10.1039/d1tb01654g. J Mater Chem B. 2021. PMID: 34505861 Review.
-
Progress and Challenges in Tumor Ferroptosis Treatment Strategies: A Comprehensive Review of Metal Complexes and Nanomedicine.Small. 2024 Jun;20(25):e2310342. doi: 10.1002/smll.202310342. Epub 2024 Jan 14. Small. 2024. PMID: 38221682 Review.
-
Targeting Ferroptosis to Iron Out Cancer.Cancer Cell. 2019 Jun 10;35(6):830-849. doi: 10.1016/j.ccell.2019.04.002. Epub 2019 May 16. Cancer Cell. 2019. PMID: 31105042 Review.
-
Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches.Drug Des Devel Ther. 2024 Jun 21;18:2485-2529. doi: 10.2147/DDDT.S472178. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38919962 Free PMC article. Review.
-
Recent progress on nanomedicine-induced ferroptosis for cancer therapy.Biomater Sci. 2021 Aug 7;9(15):5092-5115. doi: 10.1039/d1bm00721a. Epub 2021 Jun 23. Biomater Sci. 2021. PMID: 34160488 Review.
Cited by
-
PAQR3 inhibits proliferation and aggravates ferroptosis in acute lymphoblastic leukemia through modulation Nrf2 stability.Immun Inflamm Dis. 2021 Sep;9(3):827-839. doi: 10.1002/iid3.437. Epub 2021 May 6. Immun Inflamm Dis. 2021. PMID: 33955706 Free PMC article.
-
A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma.Aging (Albany NY). 2020 Jul 20;12(14):14933-14948. doi: 10.18632/aging.103553. Epub 2020 Jul 20. Aging (Albany NY). 2020. PMID: 32688345 Free PMC article.
-
Ferroptosis: A New Promising Target for Ovarian Cancer Therapy.Int J Med Sci. 2022 Oct 17;19(13):1847-1855. doi: 10.7150/ijms.76480. eCollection 2022. Int J Med Sci. 2022. PMID: 36438923 Free PMC article. Review.
-
Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma.Front Genet. 2022 Sep 20;13:927142. doi: 10.3389/fgene.2022.927142. eCollection 2022. Front Genet. 2022. PMID: 36226186 Free PMC article.
-
Ferroptosis-related genes DUOX1 and HSD17B11 affect tumor microenvironment and predict overall survival of lung adenocarcinoma patients.Medicine (Baltimore). 2024 May 31;103(22):e38322. doi: 10.1097/MD.0000000000038322. Medicine (Baltimore). 2024. PMID: 39259123 Free PMC article.
References
-
- M. Gao, X. Jiang, Curr. Opin. Cell Biol. 2018, 51, 58.
-
- L. Galluzzi, I. Vitale, S. A. Aaronson, J. M. Abrams, D. Adam, P. Agostinis, E. S. Alnemri, L. Altucci, I. Amelio, D. W. Andrews, M. Annicchiarico-Petruzzelli, A. V. Antonov, E. Arama, E. H. Baehrecke, N. A. Barlev, N. G. Bazan, F. Bernassola, M. J. M. Bertrand, K. Bianchi, M. V. Blagosklonny, K. Blomgren, C. Borner, P. Boya, C. Brenner, M. Campanella, E. Candi, D. Carmona-Gutierrez, F. Cecconi, F. K.-M. Chan, N. S. Chandel, E. H. Cheng, J. E. Chipuk, J. A. Cidlowski, A. Ciechanover, G. M. Cohen, M. Conrad, J. R. Cubillos-Ruiz, P. E. Czabotar, V. D'Angiolella, T. M. Dawson, V. L. Dawson, V. D. Laurenzi, R. D. Maria, K.-M. Debatin, R. J. DeBerardinis, M. Deshmukh, N. D. Daniele, F. D. Virgilio, V. M. Dixit, S. J. Dixon, C. S. Duckett, B. D. Dynlacht, W. S. El-Deiry, J. W. Elrod, G. M. Fimia, S. Fulda, A. J. García-Sáez, A. D. Garg, C. Garrido, E. Gavathiotis, P. Golstein, E. Gottlieb, D. R. Green, L. A. Greene, H. Gronemeyer, A. Gross, G. Hajnoczky, J. M. Hardwick, I. S. Harris, M. O. Hengartner, C. Hetz, H. Ichijo, M. Jäättelä, B. Joseph, P. J. Jost, P. P. Juin, W. J. Kaiser, M. Karin, T. Kaufmann, O. Kepp, A. Kimchi, R. N. Kitsis, D. J. Klionsky, R. A. Knight, S. Kumar, S. W. Lee, J. J. Lemasters, B. Levine, A. Linkermann, S. A. Lipton, R. A. Lockshin, C. López-Otín, S. W. Lowe, T. Luedde, E. Lugli, M. MacFarlane, F. Madeo, M. Malewicz, W. Malorni, G. Manic, J.-C. Marine, S. J. Martin, J.-C. Martinou, J. P. Medema, P. Mehlen, P. Meier, S. Melino, E. A. Miao, J. D. Molkentin, U. M. Moll, C. Muñoz-Pinedo, S. Nagata, G. Nuñez, A. Oberst, M. Oren, M. Overholtzer, M. Pagano, T. Panaretakis, M. Pasparakis, J. M. Penninger, D. M. Pereira, S. Pervaiz, M. E. Peter, M. Piacentini, P. Pinton, J. H. M. Prehn, H. Puthalakath, G. A. Rabinovich, M. Rehm, R. Rizzuto, C. M. P. Rodrigues, D. C. Rubinsztein, T. Rudel, K. M. Ryan, E. Sayan, L. Scorrano, F. Shao, Y. Shi, J. Silke, H.-U. Simon, A. Sistigu, B. R. Stockwell, A. Strasser, G. Szabadkai, S. W. G. Tait, D. Tang, N. Tavernarakis, A. Thorburn, Y. Tsujimoto, B. Turk, T. V. Berghe, P. Vandenabeele, M. G. V. Heiden, A. Villunger, H. W. Virgin, K. H. Vousden, D. Vucic, E. F. Wagner, H. Walczak, D. Wallach, Y. Wang, J. A. Wells, W. Wood, J. Yuan, Z. Zakeri, B. Zhivotovsky, L. Zitvogel, G. Melino, G. Kroemer, Cell Death Differ. 2018, 25, 486.
-
- L. R. Parisi, L. M. Morrow, M. B. Visser, G. E. Atilla-Gokcumen, ACS Chem. Biol. 2018, 13, 506.
-
- D. R. Green, Cell 2019, 177, 1094.
-
- J. P. F. Angeli, R. Shah, D. A. Pratt, M. Conrad, Trends Pharmacol. Sci. 2017, 38, 489.
Publication types
MeSH terms
Substances
Grants and funding
- 61525402/National Natural Science Foundation of China
- 61775095/National Natural Science Foundation of China
- BE2017741/Jiangsu Provincial key research and development plan
- 2017B020226001/Guangdong Provincial Science and Technology Project
- JCYJ20170818095453642/Basic Research Projects of Shenzhen Knowledge Innovation Program
LinkOut - more resources
Full Text Sources